Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Delandistrogene moxeparvovec is a gene transfer therapy approved in the United States, United Arab Emirates, and Qatar for the treatment of ambulatory patients aged four through five years with a confirmed Duchenne muscular dystrophy (DMD)-causing mutation in the DMD gene. This therapy was developed to address the underlying cause of DMD through targeted skeletal, respiratory, and cardiac muscle expression of delandistrogene moxeparvovec micro-dystrophin, an engineered, functional dystrophin protein.
METHODS: Drawing on clinical trial experience from Study 101 (NCT03375164), Study 102 (NCT03769116), and ENDEAVOR (Study 103; NCT04626674), we outline practical considerations for delandistrogene moxeparvovec treatment.
RESULTS: Before infusion, the following are recommended: (1) screen for anti-adeno-associated virus rhesus isolate serotype 74 total binding antibody titers <1:400; (2) assess liver function, platelet count, and troponin-I; (3) ensure patients are up to date with vaccinations and avoid vaccine coadministration with infusion; (4) administer additional corticosteroids starting one day preinfusion (for patients already on corticosteroids); and (5) postpone dosing patients with any infection or acute liver disease until event resolution. Postinfusion, the following are recommended: (1) monitor liver function weekly (three months postinfusion) and, if indicated, continue until results are unremarkable; (2) monitor troponin-I levels weekly (first month postinfusion, continuing if indicated); (3) obtain platelet counts weekly (two weeks postinfusion), continuing if indicated; and (4) maintain the corticosteroid regimen for at least 60 days postinfusion, unless earlier tapering is indicated.
CONCLUSIONS: Although the clinical safety profile of delandistrogene moxeparvovec has been consistent, monitorable, and manageable, these practical considerations may mitigate potential risks in a real-world clinical practice setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:153 |
|---|---|
| Enthalten in: |
Pediatric neurology - 153(2024) vom: 11. März, Seite 11-18 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mendell, Jerry R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AAVrh74 |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pediatrneurol.2024.01.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36796130X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36796130X | ||
| 003 | DE-627 | ||
| 005 | 20240312233714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pediatrneurol.2024.01.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM36796130X | ||
| 035 | |a (NLM)38306745 | ||
| 035 | |a (PII)S0887-8994(24)00014-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mendell, Jerry R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Delandistrogene moxeparvovec is a gene transfer therapy approved in the United States, United Arab Emirates, and Qatar for the treatment of ambulatory patients aged four through five years with a confirmed Duchenne muscular dystrophy (DMD)-causing mutation in the DMD gene. This therapy was developed to address the underlying cause of DMD through targeted skeletal, respiratory, and cardiac muscle expression of delandistrogene moxeparvovec micro-dystrophin, an engineered, functional dystrophin protein | ||
| 520 | |a METHODS: Drawing on clinical trial experience from Study 101 (NCT03375164), Study 102 (NCT03769116), and ENDEAVOR (Study 103; NCT04626674), we outline practical considerations for delandistrogene moxeparvovec treatment | ||
| 520 | |a RESULTS: Before infusion, the following are recommended: (1) screen for anti-adeno-associated virus rhesus isolate serotype 74 total binding antibody titers <1:400; (2) assess liver function, platelet count, and troponin-I; (3) ensure patients are up to date with vaccinations and avoid vaccine coadministration with infusion; (4) administer additional corticosteroids starting one day preinfusion (for patients already on corticosteroids); and (5) postpone dosing patients with any infection or acute liver disease until event resolution. Postinfusion, the following are recommended: (1) monitor liver function weekly (three months postinfusion) and, if indicated, continue until results are unremarkable; (2) monitor troponin-I levels weekly (first month postinfusion, continuing if indicated); (3) obtain platelet counts weekly (two weeks postinfusion), continuing if indicated; and (4) maintain the corticosteroid regimen for at least 60 days postinfusion, unless earlier tapering is indicated | ||
| 520 | |a CONCLUSIONS: Although the clinical safety profile of delandistrogene moxeparvovec has been consistent, monitorable, and manageable, these practical considerations may mitigate potential risks in a real-world clinical practice setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AAVrh74 | |
| 650 | 4 | |a Adeno-associated virus (AAV) | |
| 650 | 4 | |a Delandistrogene moxeparvovec | |
| 650 | 4 | |a Duchenne muscular dystrophy | |
| 650 | 4 | |a Gene therapy | |
| 650 | 4 | |a Practical considerations | |
| 650 | 4 | |a Safety | |
| 650 | 7 | |a Dystrophin |2 NLM | |
| 650 | 7 | |a Troponin I |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Proud, Crystal |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidman, Craig M |e verfasserin |4 aut | |
| 700 | 1 | |a Mason, Stefanie |e verfasserin |4 aut | |
| 700 | 1 | |a Darton, Eddie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shufang |e verfasserin |4 aut | |
| 700 | 1 | |a Wandel, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Alexander P |e verfasserin |4 aut | |
| 700 | 1 | |a Mercuri, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Muntoni, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, Craig M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric neurology |d 1993 |g 153(2024) vom: 11. März, Seite 11-18 |w (DE-627)NLM012947210 |x 1873-5150 |7 nnns |
| 773 | 1 | 8 | |g volume:153 |g year:2024 |g day:11 |g month:03 |g pages:11-18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pediatrneurol.2024.01.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 153 |j 2024 |b 11 |c 03 |h 11-18 | ||